Tag: age-related macular degeneration
The AREDS2: No benefit from additional carotenoid and omega-3-fatty acid supplementation to original AREDS formulation [The Classics Series]
Carl Shen -0
1. There was no added benefit observed with adding lutein and zeaxanthin, omega-3-fatty acids (DHA and EPA), or the combination to the original AREDS formulation in reducing progression to advanced age-related macular degeneration (AMD) in high-risk patients.
2. Because of the suspected association between beta-carotene and increased lung cancer risk...
The AREDS1: Zinc and antioxidant supplementation reduce progression of AMD in high-risk patients [The Classics Series]
Carl Shen -
1. In patients with advanced age-related macular degeneration (AMD) in one eye only or intermediate AMD in either eye, zinc and antioxidant supplementation reduced the risk of progression to advanced AMD and reduced the risk of moderate vision loss.
2. In patients with early stage AMD, supplementation did not reduce...
The CATT study: Avastin and Lucentis equally effective for macular degeneration [Classics Series]
Swarup Swaminathan, MD -
1. Lucentis (ranibizumab) and Avastin (bevaciumab) demonstrated equivalent effects on visual acuity in age-related macular degeneration (AMD) patients after 1 year of treatment.
2. There was no difference in final visual acuity between injections completed as needed based on exam findings and injections completed on a monthly schedule.
Original Date of Publication:...
1. Treatment with human-embryonic stem cell-derived (hESC-derived) retinal pigment epithelium led to improved visual acuity and vision-related quality-of-life measures for patients with age-related macular degeneration and Stargardt’s macular dystrophy.
2. No evidence of serious ocular or systemic safety issues, adverse proliferation, or rejection related to the hESC-derived tissue was...
No increased overall risk of systemic events with use of anti-VEGF eye treatments
Swarup Swaminathan, MD -
1. There was no overall increase in systemic cardiovascular events with the use of antibodies to vascular endothelial growth factor (anti-VEGF) therapies in the eye (Avastin or Lucentis).
2. Subgroup analysis indicated a significant increase in clot formation with Avastin use and an increase in bleeding with age-related macular degeneration...
Vasodilators associated with increased risk of age-related macular degeneration
Swarup Swaminathan, MD -
Image: PD
1. After adjustments, use of vasodilators or ß-blockers were significantly associated with increased risk of early and late age-related macular degeneration (AMD), respectively.
2. In particular, oral nitroglycerin use was significantly associated with early AMD.
Evidence Rating Level: 2 (Good)
Study Rundown: Vasodilators are thought to stimulate the growth of subretinal vessels due to...
Image: PD
1. 8 predictors (age, sex, education level, race, smoking status, presence of pigment abnormality, soft drusen, and maximum drusen size) were utilized to create a macular risk scoring system (MRSS).
2. Area under the receiver operating characteristic (ROC) curve was excellent (internally validated c-index = 0.88; externally validated c-index...
Image: PD
1. Previous large-scale studies have demonstrated a benefit of oral vitamin and mineral antioxidants for lowering the risk of age-related macular degeneration.
2. In the present study, the authors show no additional benefit over placebo for adding oral retinal pigment proteins or long-chain fatty acids to these supplements.
Evidence Rating Level:...